Ipsos Healthcare Debuts Severe Asthma Therapy Monitor

Ipsos Healthcare has launched a syndicated study called the Severe Asthma Therapy Monitor, in the US, with other markets to follow.

As part of the Ipsos Global Therapy Monitor Portfolio, the new study will combine actual patient data with the perceptions of treating doctors. Specifically, the study will measure actual market share and key drivers for treatment choice, and has been designed to help clients understand how people progress through the 'patient pathway', size the opportunity for 'novel agents' and identify which patients are more likely to switch to novel therapies. It will also pinpoint which attributes doctors rate as most important in prescribing in this niche area and how specific products perform.

Dr Sabina Heinz, Director of Real World Evidence in Global Diseases, comments: 'Currently, the severe asthma market is in an exciting phase, as powerful new treatments either have been or are soon to be launched, potentially transforming the lives of these patients. Ipsos' Therapy Monitor will be there to monitor the uptake of these new biologics in the market. This will give our clients the real-world evidence they need to ascertain the impact of their drugs, both on the market and on the patient population'.

Web site: www.ipsos.com .